ORIC Pharmaceuticals Secures $244M, Reports Strong Phase 1b Data in Prostate and Lung Cancer
ORIC reported Phase 1b data for rinzimetostat in mCRPC with 55% PSA50 and 20% PSA90 response rates, and enozertinib showed 67% systemic ORR and 100% intracranial ORR in EGFR exon 20 NSCLC. The company raised $244 million and holds $413 million cash to fund operations into second half of 2028.
1. 2025 Operational Highlights and Rinzimetostat Progress
ORIC Pharmaceuticals completed Phase 1b dose exploration for rinzimetostat (ORIC-944) in metastatic castration-resistant prostate cancer, selecting provisional Phase 2 doses for combination with darolutamide and apalutamide. In a 20-patient cohort, 55% achieved a confirmed PSA50 response and 20% a confirmed PSA90 response. Circulating tumor DNA analyses in 17 evaluable patients showed >50% reduction in 76% and complete ctDNA clearance in 59%, exceeding benchmarks from standard of care studies. Treatment-related adverse events were predominantly Grade 1 or 2, supporting long-term dosing.
2. Enozertinib Phase 1b Data in NSCLC
In non-small cell lung cancer patients with EGFR exon 20 or PACC mutations, enozertinib demonstrated 67% objective response rate (ORR) in second-line exon 20 cases and 80% ORR in PACC. First-line intracranial activity was 100% ORR for both mutation cohorts in patients with measurable brain metastases. Systemic first-line ORR benchmarks also compared favorably to competitors, and safety data showed low discontinuation rates due to off-target toxicity. ORIC initiated a collaboration with Johnson & Johnson on a trial combining enozertinib with SC amivantamab for first-line treatment.
3. Strengthened Financial Position and Leadership Expansion
During 2025 ORIC raised $244 million in gross proceeds from top-tier healthcare specialist funds through a private placement and at-the-market program. As of September 30, 2025, the company held $413 million in cash and investments, providing runway into the second half of 2028. ORIC also appointed Kevin Brodbeck, PhD, as Chief Technical Officer and enhanced its executive team to advance registrational trial preparations.
4. Upcoming Milestones for 2026
ORIC anticipates reporting combination dose optimization data for rinzimetostat with AR inhibitors in the first quarter, followed by initiation of a global Phase 3 registrational trial in the first half. For enozertinib, monotherapy and combination data in first-line EGFR exon 20 and PACC NSCLC cohorts are expected in the second half. Multiple clinical data readouts across both programs are planned throughout 2026, positioning ORIC for registrational trial initiations and potential value inflection points.